Traws Pharma Signs $50M Equity Line With Roth Principal Investments

summarizeSummary

Traws Pharma signed a $50 million equity line of credit with Roth Principal Investments, letting it sell new shares at a 6% discount to market over about three years. No shares have been sold yet; the deal provides standby capital but carries dilution and a 19.99% exchange cap.

check_boxKey Events · Financing and Capital Events · TRAW

• New $50M Equity Line With Roth

  Traws Pharma entered a Common Stock Purchase Agreement dated October 23, 2026, giving it the right, at its sole discretion, to sell up to $50,000,000 in aggregate gross purchase price of newly issued common stock to Roth Principal Investments over a term ending the first day of the month after the 36-month anniversary of the Commencement Date.

• Pricing at 6% Discount to VWAP

  Shares sold under Market Open, Intraday, Pre-Market, Post-Market and Block purchases are priced at 94.0% of the applicable VWAP (or 94.0% of the closing sale price for Block Purchases), a fixed 6.0% discount; the Threshold Price is $0.10 per share and the Base Price/Minimum Price is $0.3663.

• Exchange Cap Limits Issuance

  Absent stockholder approval, the company may issue no more than 3,072,118 shares under the agreement — 19.99% of shares outstanding immediately prior to execution — and Roth is capped at 4.99% beneficial ownership.

• Fees and Restrictions

  The company agreed to pay $50,000 to Compass Point as qualified independent underwriter and $100,000 ($25,000 already paid) to reimburse Roth's legal counsel, plus up to $7,500 per fiscal quarter; it is also barred from Variable Rate Transactions during the term, with carve-outs including its existing ATM program.

auto_awesomeAnalysis · TRAW · Life Sciences

Traws Pharma now holds the right — though not the obligation — to sell up to $50 million of new stock to Roth Principal Investments over roughly three years at 94% of the volume-weighted average price, a fixed 6% discount. No shares have been sold yet; this is a standby funding source, not cash in hand. For a company that previously disclosed a going-concern warning and a Nasdaq delisting notice, a committed equity buyer is a survival tool, but the terms are costly: every drawdown dilutes existing holders at a 6% discount, and the 3,072,118-share exchange cap (19.99% of current shares outstanding) limits how much can be sold without a shareholder vote. The company also agreed to pay $50,000 to Compass Point as qualified independent underwriter and $100,000 to reimburse Roth's legal fees, and it is barred from other variable-rate financings while the agreement is live.